Gene Editing and Human IPSCs in Cardiovascular and Metabolic Diseases

Overview

Journal Adv Exp Med Biol

Specialties Biology
General Medicine

Date 2022 Dec 1

PMID 36454473

Authors

Sebastiano Giallongo

Oriana Lo Re

Igor Resnick

Marco Raffaele

Manlio Vinciguerra

Affiliations

Soon will be listed here.

Abstract

The incidence and the burden of cardiovascular disease (CVD), coronary heart disease (CHD), type 2 diabetes mellitus (T2DM), and the metabolic syndrome are greatly increasing in our societies. Together, they account for 31% of all deaths worldwide. This chapter focuses on the role of two revolutionary discoveries that are changing the future of medicine, induced pluripotent stem cells (iPSCs) and CRISPR/Cas9 technology, in the study, and the cure of cardiovascular and metabolic diseases.We summarize the state-of-the-art knowledge about the possibility of editing iPSC genome for therapeutic applications without hampering their pluripotency and differentiation, using CRISPR/Cas technology, in the field of cardiovascular and metabolic diseases.

Citing Articles

Generation of Isogenic iPSC Lines for Studying the Effect of the p.N515del (c.1543_1545delAAC) Variant on MYBPC3 Function and Hypertrophic Cardiomyopathy Pathogenesis.

Pavlova S, Shulgina A, Minina J, Zakian S, Dementyeva E Int J Mol Sci. 2024; 25(23).

PMID: 39684611 PMC: 11641397. DOI: 10.3390/ijms252312900.

References

Takahashi K, Yamanaka S . Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126(4):663-76. DOI: 10.1016/j.cell.2006.07.024. View

Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K . Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131(5):861-72. DOI: 10.1016/j.cell.2007.11.019. View

Yu J, Vodyanik M, Smuga-Otto K, Antosiewicz-Bourget J, Frane J, Tian S . Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007; 318(5858):1917-20. DOI: 10.1126/science.1151526. View

Gurdon J . The developmental capacity of nuclei taken from intestinal epithelium cells of feeding tadpoles. J Embryol Exp Morphol. 1962; 10:622-40. View

Wilmut I, Schnieke A, McWhir J, Kind A, Campbell K . Viable offspring derived from fetal and adult mammalian cells. Nature. 1997; 385(6619):810-3. DOI: 10.1038/385810a0. View

Tada M, Takahama Y, Abe K, Nakatsuji N, Tada T . Nuclear reprogramming of somatic cells by in vitro hybridization with ES cells. Curr Biol. 2001; 11(19):1553-8. DOI: 10.1016/s0960-9822(01)00459-6. View

Barrangou R . The roles of CRISPR-Cas systems in adaptive immunity and beyond. Curr Opin Immunol. 2015; 32:36-41. DOI: 10.1016/j.coi.2014.12.008. View

Horvath P, Barrangou R . CRISPR/Cas, the immune system of bacteria and archaea. Science. 2010; 327(5962):167-70. DOI: 10.1126/science.1179555. View

Marraffini L, Sontheimer E . CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA. Science. 2008; 322(5909):1843-5. PMC: 2695655. DOI: 10.1126/science.1165771. View

10.

Hsu P, Lander E, Zhang F . Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014; 157(6):1262-1278. PMC: 4343198. DOI: 10.1016/j.cell.2014.05.010. View

11.

Barrangou R, Marraffini L . CRISPR-Cas systems: Prokaryotes upgrade to adaptive immunity. Mol Cell. 2014; 54(2):234-44. PMC: 4025954. DOI: 10.1016/j.molcel.2014.03.011. View

12.

Szczepankowska A . Role of CRISPR/cas system in the development of bacteriophage resistance. Adv Virus Res. 2012; 82:289-338. DOI: 10.1016/B978-0-12-394621-8.00011-X. View

13.

Hille F, Richter H, Wong S, Bratovic M, Ressel S, Charpentier E . The Biology of CRISPR-Cas: Backward and Forward. Cell. 2018; 172(6):1239-1259. DOI: 10.1016/j.cell.2017.11.032. View

14.

Deltcheva E, Chylinski K, Sharma C, Gonzales K, Chao Y, Pirzada Z . CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature. 2011; 471(7340):602-7. PMC: 3070239. DOI: 10.1038/nature09886. View

15.

Bolotin A, Quinquis B, Sorokin A, Ehrlich S . Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. Microbiology (Reading). 2005; 151(Pt 8):2551-2561. DOI: 10.1099/mic.0.28048-0. View

16.

Makarova K, Grishin N, Shabalina S, Wolf Y, Koonin E . A putative RNA-interference-based immune system in prokaryotes: computational analysis of the predicted enzymatic machinery, functional analogies with eukaryotic RNAi, and hypothetical mechanisms of action. Biol Direct. 2006; 1:7. PMC: 1462988. DOI: 10.1186/1745-6150-1-7. View

17.

Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S . CRISPR provides acquired resistance against viruses in prokaryotes. Science. 2007; 315(5819):1709-12. DOI: 10.1126/science.1138140. View

18.

Deveau H, Barrangou R, Garneau J, Labonte J, Fremaux C, Boyaval P . Phage response to CRISPR-encoded resistance in Streptococcus thermophilus. J Bacteriol. 2007; 190(4):1390-400. PMC: 2238228. DOI: 10.1128/JB.01412-07. View

19.

Garneau J, Dupuis M, Villion M, Romero D, Barrangou R, Boyaval P . The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature. 2010; 468(7320):67-71. DOI: 10.1038/nature09523. View

20.

Makarova K, Aravind L, Wolf Y, Koonin E . Unification of Cas protein families and a simple scenario for the origin and evolution of CRISPR-Cas systems. Biol Direct. 2011; 6:38. PMC: 3150331. DOI: 10.1186/1745-6150-6-38. View